

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68, C07K 14/47, 16/18, C12N 15/12, 15/00, 5/10, A61K 38/16, A01K 67/027</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/23252</b> <b>(43) International Publication Date:</b> 14 May 1999 (14.05.99)
<b>(21) International Application Number:</b> PCT/GB98/03375 <b>(22) International Filing Date:</b> 5 November 1998 (05.11.98)  <b>(30) Priority Data:</b> 9723412.4 5 November 1997 (05.11.97) GB 9818118.3 19 August 1998 (19.08.98) GB  <b>(71) Applicant (for all designated States except US):</b> ISIS INNOVATION LIMITED [GB/GB]; 2 South Parks Road, Oxford, Oxfordshire OX1 3UB (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BAKKENIST, Christopher, James [GB/GB]; 11 Woolaston Drive, Alsager, Stoke-on-Trent, Staffordshire ST7 2PL (GB). KORETH, John [IN/IN]; A-10/45 Mall Road, 110054 Delhi (IN). McGEE, James, O'Donnell [GB/GB]; 17 Cadagan Park, Woodstock, Oxfordshire OX40 1UW (GB).  <b>(74) Agents:</b> PRIVETT, Kathryn, L. et al.; Stevens, Hewlett & Perkins, 1 Serjeants' Inn, Fleet Street, London EC4Y 1LL (GB).	<b>(81) Designated States:</b> AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> CANCER GENE  <b>(57) Abstract</b>  Methods and reagents for diagnosing neoplasia or a susceptibility to neoplasia are provided, which methods comprise detecting the aberrant expression of a gene at the heat shock cognate 73 (HSC73) locus or detecting a mutation at the HSC73 locus. Such methods are useful for example in the detection and/or prediction of carcinomas of the breast.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

### CANCER GENE

This invention relates to methods of diagnosing neoplasia or a susceptibility to neoplasia, in particular malignant neoplasia, which  
5 method is based on detecting abnormalities in or affecting the HSC73 (Heat Shock Cognate 73) gene (and/or gene products). The invention further relates to reagents for use in such methods. The invention also relates to genetically modified non-human mammals having a general weakness or a predisposition to cancer and/or other diseases, as a result  
10 of a genetic modification to or affecting a HSC73 gene.

Cancer results from the accumulation of somatically acquired genetic changes, sometimes associated with inherited predisposing germline mutation. The initiation of tumour development is considered an irreversible genetic change that occurs in cells either spontaneously or  
15 upon exposure to chemical and physical agents. A selective expansion of initiated cells then occurs with a concurrent increase in genetic lesions. In the final stage of tumour development, progression, sufficient mutations in oncogenes and tumour suppresser genes accumulate to irreversibly remove the cells from growth control. Mutations which promote malignancy  
20 are expected to result in the dysfunction or loss of proteins which protect DNA from damage, proteins which repair DNA and proteins involved in cell cycle checkpoints which control the normal chromosome complement. Therefore, while there is a selection of mutations which remove the normal cell from growth control, many mutations which have no function in tumour  
25 promotion will also accumulate as a result of damage to genome maintenance proteins. Identification of mutational events which cause cancer and the characterisation of their gene products will enable better diagnosis and ultimately treatment for cancer sufferers. Identification of cancer-related genes will also enable the development of model systems  
30 for testing toxicity (in particular carcinogenicity) of chemicals and biochemicals for use e.g. in pharmaceutical, pesticide and other

compositions.

The kinetics of age incidence of cancer in mice indicate that six or seven gene hits are required to produce the malignant phenotype. This makes any mouse model of carcinogenesis slow and generally  
5 dependent on random genotoxic events. A model of susceptibility is required which has a totally defined background. Mice with a specific gene mutation (e.g. *TRP53*), gene amplification (e.g. *Hras*) or expressing a viral gene (e.g. *HBV-X*) are not good models for carcinogenesis testing since a specific pathway which results in the malignant phenotype is compromised.  
10 Only those carcinogens which promote cancer via the specific compromised pathway would be detected using such a model.

A mouse is needed which is compromised in all pathways which can result in the malignant phenotype but which is not initiated or committed in any of them. What is needed is a hemizygous mouse which  
15 is compromised generally in homeostasis; compromised but not initiated to neoplasia by any specific pathway. Such a mouse model would detect all agents which can promote cancer, in a shorter period than an unmodified mouse, since less gene hits should be required.

Despite the screening programmes in place in recent years,  
20 breast cancer remains a major problem, with a death rate of 15,000 women per annum in the United Kingdom. Better screening techniques are therefore needed. Where suspected breast cancer is detected at an early stage, surgical removal can be an effective treatment. However, the two generally accepted potential precursors to breast cancer, ductal carcinoma  
25 *in situ* (DCIS) and lobular carcinoma *in situ* (LCIS), only actually result in malignant (invasive) disease in about 25% of DCIS cases and 20% of LCIS cases. Thus, it would be of significant benefit to be able to identify DCIS and LCIS and other lesions which are actual precursors to invasive breast cancer.

30 For some time, the long arm of chromosome 11 (11q) has been implicated in malignancy. An anonymous locus at 11q22.3 (D11S29)

- 3 -

was found to be deleted in a significant number of breast cancers.

Subsequently the incidence of 11q allelic deletions in breast cancer was examined by Southern blot analysis in paired fresh normal and breast cancer tissue (1,2). Of 41 patients with sporadic breast cancer, 59% were shown to have lost one allele at the D11S29 locus. Four other probes (D11Z1, INT2, DRD2, ETS1) proximal and distal to D11S29 did not show allelic deletion. This study was expanded by a microsatellite PCR study. Of 83 patients who were heterozygous at D11S29, 42 % demonstrated allelic imbalance (3).

To finely map the deletion event(s) in breast cancer, paraffin embedded archival tissue was examined by PCR with multiple microsatellite markers. It was found that the region 11q22-q23.1 (8cM) was deleted in 63% of sporadic breast cancers and a novel region of allelic deletion at chromosome 11q25 (2cM) was also identified in 51% of the cases studied (4). In all, deletions along 11q were present in 72% of sporadic breast cancers. When contrasted with a 10% "background" rate of allelic deletion in colorectal carcinomas, these data are strongly indicative of genetic events occurring at chromosome 11q22-q23.1 and 11q25 which may be of importance in the pathogenesis of breast cancer. The deletion event at 11q22-23.1 has been examined in DCIS (a putative pre-invasive lesion) in patients with concomitant invasive cancer. Of 18 patients, 17 were concordant for deletion/or its absence at D11S29 (3). Further allelic deletion at this locus was present in lymph node metastasis (75%) from carcinomas with the deletion. Allelic deletions in invasive breast cancer have been confirmed by others at 11q22-24 (5) or 11q22-23 (6).

Deletion events at 11q22-24 have also been described in 40% of invasive cervical cancers (7) and 67% of matched pairs of normal and melanoma tissue from non familial patients (8). We have also shown the deletion at 11q22-24 in 8 of 108 informative cases of pure CIN3 (cervical intraepithelial neoplasia, Grade III) (9). Given that it takes 5-15

- 4 -

years for CIN3 to progress to invasive cancer (when it does indeed progress), these and the DCIS data indicate that allelic deletion at 11q22-24 may be an early event in the neoplastic process. Deletions of 11q have also been described in ovarian cancer (11q22-24) (10), gastric cancer (11) and lung cancer (12). Collating the allelic deletion data along 11q for all tumour types (see Figure 1), 3 minimal regions of allelic loss have been identified at 11q22-23.1, 11q23.3-24 and 11q25-qter (13). This suggests genetic rearrangement events along chromosome 11q may accumulate affecting up to 3 specific loci during the development of these carcinomas.

Several other lines of evidence implicate chromosome 11q in malignancy. Cytogenetic analysis of breast cancer has demonstrated anomalies at 11q22-25 (14). Numerical aberrations in chromosome 11 and 17, and chromosome 11 and 17 inequality, have been correlated with lymph node metastases or disseminated disease in breast cancer patients (15). Since the 1980's, micro-cell transfer has implicated chromosome 11 as a potent tumour suppresser source in cervical derived HeLa cervical cancer cells (16). Functional tumour suppression with chromosome 11q has also been shown in breast (6), lung (17) and melanoma (18) cell lines and metastasis suppression has been identified in the MDA breast cancer cell line (19).

Thus, although mutations in certain regions of chromosome 11q have been linked to cancer, no basis has been provided for a reliable test relating to this. The regions of the chromosome involved have been until now too large and non-specific. For example, the region of the chromosome from 11q23.3 to 11q25 is greater than 10 megabases long and possibly contains 50 or more genes (most of which are as yet unidentified).

The first murine heat shock cognate sequence published was that of a clone obtained from a teratocarcinoma derived cell line (F9) from the 129/SvJ strain of mouse (27). This sequence was named HSC72. Subsequently a second heat shock cognate sequence was published and

- 5 -

named HSC73 (28). These two sequences differ by a point mutation in exon 3 which results in a single amino change at position 129 from Asp to Asn.

It has now been discovered by the inventors that mutant products of a gene which was originally cloned in 1987 (20), the human Heat Shock Cognate 73 (HSC73), are involved in cancer. HSC73 had previously been located to chromosome 11q23.3-q25 (21) and has in the past been referred to in humans as HSC70 and HSC71. HSC73 is normally present in 2 copies, one on each chromosome 11.

The following observations have been made:

- HSC73 has been fine-mapped to a YAC (yeast artificial chromosome) at 11q23.3.
- HSC73 expression is qualitatively aberrant by Northern blotting, RT-PCR (reverse transcriptase-PCR) and sequencing in 70% of RNA samples extracted from immortalised malignant breast cell lines and non-familial (i.e. sporadic) breast cancers, but not in paired constitutional samples (both breast and skin). Sequencing demonstrates that the aberrant transcripts are generally interstitial deletions of a large number of exons encoding the HSC73 protein (typically covering exon 2 or 3 to exon 9) with break points in exons.
- HSC73 is therefore aberrant at the RNA level in 70% of sporadic breast cancers.
- The expression of this gene in breast tissue has also been examined directly by RNA *in situ* hybridisation and immunohistochemistry using polyclonal antibodies raised against synthetic peptides. The tumour cells show either absent or reduced expression of HSC73 RNA in 70% of sporadic breast carcinomas and 50% of DCIS.
- Breast tumours show increased expression of HSC73 protein in approximately 70% of cases (it is believed that this results from the accumulation of mutated protein).
- It is anticipated that the mutated HSC73 RNA is a result of mutated

DNA in these cases and results from point mutations. Evidence for this is discussed herein.

- Disruption of HSC73 gene products has been found in cancers other than breast cancer, for example cervical and colorectal carcinoma and a malignant lymphocytic cell line (for which mutated transcripts have been detected).

Further to these findings we have also discovered DNA mutations in the human HSC73 gene in clinical carcinomas of the breast. This has been achieved by PCR amplification of individual exons of HSC73 at 11q23.3 using oligonucleotide sequences within the introns of the gene from DNA extracted from clinical carcinomas of the breast. Pseudogenes have not been amplified since the oligonucleotide sequences are specific for the genomic HSC73 locus at 11q23.3. All amplified DNA fragments have been sequenced. Intron sequences confirmed the fragments were genomic sequences of HSC73 at 11q23.3.

The DNA mutations so far identified in HSC73 in clinical carcinomas of the breast are generally point mutations and small insertions/deletions of sequence. The mutations are described in Example 1. The mutations identified in HSC73 are in exon 3 (the second coding exon) of the gene and are not present in DNA purified from adjacent non-malignant breast tissue or skin from the same patient. These nucleotide changes result in amino acid substitutions. The nucleotide changes and amino acid substitutions are listed in Example 1. This suggests that some change(s) in HSC73 protein function (either gain or loss) is acquired as a result of mutation in exon 3 which confers a growth advantage to the tumour cell. Exon 3 is critical for the ATPase activity of the protein (O'Brien *et al* 1996, J. Biol. Chem. 271; 15874-8).

Allelic imbalance data implicates 11q23.3 as the location of a multi-tumour suppressor gene. The HSC73 gene maps to this location and is mutated in human clinical carcinomas of the breast.

Disruption of HSC73 is expected to be involved in a wide



- 7 -

variety of malignant and non-malignant diseases. The protein encoded by HSC73 is an essential component of the centrosome (22), a genome caretaker (23), a participant in protein degradation pathways (24 – subsequently independently confirmed) and essential for maintaining  
5 proteins in a semi folded state in order to enable translocation through the mitochondrial and endoplasmic reticulum (it is therefore essential for steroid hormone receptor activation) (25).

The deletions in the RNA encoding HSC73 which have been characterised in malignant disease also delete three small nucleolar RNAs  
10 14 (SNURPs) which are essential for ribosome biosynthesis and 18S rRNA processing (26). The three SNURPs are encoded by short sequences in introns 5, 6 and 8 of HSC73.

The invention provides in one aspect a method of diagnosis performed on a biological sample, which method comprises detecting the  
15 aberrant expression of a gene at the HSC73 locus, or detecting a mutation at the HSC73 locus, in the sample.

Such a method is useful in particular for diagnosing neoplasia or a susceptibility to neoplasia, especially malignant neoplasia. The diagnosis may be a predictive diagnosis, for example it may predict  
20 whether or not *in situ* neoplasia such as DCIS will become invasive.

In further aspects, the invention provides novel reagents for use in the method according to the invention. Such reagents include but are not limited to:

i) Oligonucleotides and panels of oligonucleotides capable of  
25 indicating the presence of a mutation at the HSC73 locus by hybridising or by not hybridising to DNA or RNA. Such oligonucleotides may be employed as primers or probes. The invention is concerned in particular with oligonucleotides which hybridise specifically under stringent conditions, to exon 3 or a region of exon 3 of the HSC73 gene. The  
30 oligonucleotides may be specifically complementary either to the wild type HSC73 sequence or to a mutant HSC73 sequence.

- 8 -

ii) Monoclonal antibodies and panels of monoclonal antibodies capable of indicating the presence of a protein product of a mutant HSC73. The invention is concerned in particular with antibodies which bind specifically to a region of the HSC73 protein encoded by exon 3, especially mutated exon 3. Such antibodies can be easily raised for example using recombinant HSC73 polypeptides or peptides generated using known techniques.

The invention further provides synthetic peptides capable of generating such antibodies and isolated or recombinant proteins or polypeptides capable of generating such antibodies.

In still another aspect, the invention provides a genetically modified non-human mammal having genetic weakness to disease, in which the somatic cells and germ cells have at least one mutated or deleted copy of HSC73. Such genetically modified animals will be susceptible to cancer by a variety of pathways, since their control of homeostasis is weak. At the neonatal stage, they will generally be healthy animals which are not initiated in any cancer pathway.

The invention further provides an embryonic stem cell transformed with a nucleic acid capable of replacing a copy of HSC73 in the cell. The nucleic acid may be either a mutated copy of HSC73, or a marker such as a drug resistance marker. Such a cell may be regenerated into a genetically modified animal according to the invention.

The invention provides in yet another aspect a cell line genetically engineered to have at least one mutated or deleted copy of HSC73. Genetically modified HSC73 cell lines will be useful as targets for therapeutic testing and development of anti-cancer agents.

In another aspect the invention provides a method of testing a compound for biological activity, particularly toxicity, which method comprises exposing a cell line or a genetically modified non-human mammal according to the invention, to the compound.

The invention also provides kits for diagnostic and screening

- 9 -

purposes, in particular a kit for performing a method of diagnosis described herein which kit comprises an oligonucleotide which hybridises specifically to a DNA which encodes a mutated or unusual polymorphic form of an HSC73 mRNA or peptide, and not to a DNA which encodes wild type HSC73 mRNA or peptide. Alternative kits are provided for detecting aberrant HSC73 protein and mRNA levels as described herein.

Furthermore, the invention provides uses in gene therapy. Thus, the invention provides a method of treatment comprising introducing into a patient at least one copy of a nucleic acid which encodes a native HSC73 under the control of a suitable promoter; and a composition comprising a gene delivery vector which comprises a nucleic acid encoding an HSC73 protein under the control of a suitable promoter, together with a pharmaceutically acceptable carrier. Suitable vectors for delivery of the nucleic acid are well known in the art of gene therapy, as also are appropriate promoters for the expression of the HSC73 protein *in vivo*. The introduction of a gene in gene therapy may be carried out on cells *in vitro* which cells are then introduced or reintroduced into the patient, or it may be carried out by delivery of the gene to cells *in vivo*.

In addition, the invention will be useful in the development of new anti-cancer therapies. Pharmaceutical agents which can upregulate or replace a function of HSC73 or which are inhibitory to mutated HSC73 may be beneficial. Mutated HSC73 may indicate tumour susceptibility to individualised therapeutic protocols. Gene or protein replacement therapy for HSC73 in malignant tissue may also be beneficial, since HSC73 is ubiquitously expressed. A suitable experimental model for the technical development of gene therapy would be a genetically modified mouse or other non-human mammal model, such as a hemizygous HSC73 "knockout" mouse model. As well as novel therapies directed to DNA (gene therapy), therapies directed to RNA (antisense technology) and proteins (binding, modifying agents and immunotherapy) are also feasible.

The human HSC73 sequence is found at GenBank Accession

Number Y00371 (see Figure 5). The murine HSC73 sequence is found at GenBank Accession Number J17982.

Figure 1 shows an ideogram of chromosome 11, focusing on the 11q22-qter region. Marker loci are arrayed vertically (inter marker distance not to scale) and tumour types listed horizontally. Thick vertical lines indicate minimum regions of deletion reported (references in text), and barred boxes show consensus regions of deletion between different reports, for a given tumour type. Regions 1 and 2 show possible localisation of multi-tumour suppressor genes deleted in above tumour types. HSC73 maps to region 2.

The invention will now be described in more detail below. It will be understood that the following description is illustrative and is not intended to limit the scope of the invention in any way.

#### **Diagnostic and Prognostic Techniques**

Some of the possible techniques and reagents for use in the invention are as follows:

1) Immunohistochemistry (on fresh and formalin fixed paraffin embedded tissue)

The gene which encodes HSC73 has nine exons, eight of which are coding. The gene is mutated at the DNA and/or the RNA level in a high percentage of cases of several types of tumour (see below). This leads to aberrant expression of HSC73. We have characterised the expression of HSC73 protein in malignant disease of the breast, ovary, prostate and lung using a commercially available goat polyclonal antibody raised against a synthetic peptide which bridges exons eight and nine of the HSC73 gene (Santa Cruz Biotechnology, Inc. product HSC70 (K19) catalogue number sc-1059). The expression of HSC73 in the tumours listed detected with the polyclonal antibody, is increased over normal tissue in approximately 80% of cases. The expression of HSC73 in other malignant disease (e.g. cervix, colon, stomach and skin) can be easily

- 11 -

characterised using this antibody and correlated with diagnostic and prognostic data.

Further, since the gene encoding HSC73 can be mutated both at the DNA and/or RNA level, a panel of monoclonal antibodies raised  
5 against synthetic peptides with one antibody against each coding exon, can be used to characterise the expression of HSC73 in malignant tissue. The expression of HSC73 detected with each of these antibodies is correlated with diagnostic and prognostic data and with the expression detected by other antibodies. Increased expression of the protein detected with an  
10 antibody against one exon may reflect an increased expression of the gene from one (or both) alleles or an accumulation of mutated HSC73 which cannot be degraded correctly. A reduction in expression detected by an antibody may reflect a deletion in the gene either at the DNA and/or RNA level which removes an amino acid sequence from HSC73 expressed from  
15 one or both alleles; or it may reflect deletion of the entire gene from one (or possibly both) alleles.

The full sequences for both copies of the gene in malignant breast tissue and in paired normal tissue can be obtained by standard techniques. If a conserved point mutation(s) is detected which affects  
20 protein sequence(s), a synthetic peptide(s) corresponding to this sequence may be prepared and a monoclonal antibody raised against it which is specific to the mutant protein. The expression of HSC73 detected with one or more such antibodies is then correlated with diagnostic and prognostic data.

25 It is anticipated that an antibody or a combination of such antibodies may be used for detection of aberrant HSC73 expression which will be of use in a routine histopathology laboratory for:

- Diagnosis of neoplasia (invasive and *in situ*)
- Prognosis of malignancy (invasive disease).
- 30 - Prognosis of *in situ* neoplasias such as DCIS/LCIS and CIN3.

- 12 -

2) RNA *in situ* hybridisation (on fresh and formalin fixed paraffin embedded tissue).

We have characterised the expression of HSC73 mRNA in malignant disease of the breast, ovary, prostate and lung using a synthetic antisense oligonucleotide complementary to exon nine. The expression of HSC73 mRNA in these tumours detected with this synthetic oligonucleotide is decreased in comparison to normal tissue in approximately 80% of cases. The expression of HSC73 mRNA in other malignant disease (e.g. cervix, colon, stomach and skin) can be easily characterised using this synthetic oligonucleotide and correlated with diagnostic and prognostic data.

Further, since the gene encoding HSC73 can be mutated both at the DNA and/or RNA level, an antisense oligonucleotide against each coding exon can be used to characterise the expression of HSC73 mRNA in malignant tissue from all tissues. The expression of HSC73 mRNA detected with each of these synthetic oligonucleotides is correlated with diagnostic and prognostic data and with the other oligonucleotide. Increased expression of the RNA detected with an oligonucleotide against one exon may reflect an increased expression of the gene from one (or both) alleles or it may reflect an accumulation of mutated HSC73 mRNA which cannot be degraded correctly. A reduction in expression detected by a synthetic oligonucleotide may reflect mutation in the gene at the DNA and/or RNA level, which removes the target sequence from the HSC73 mRNA expressed from one or both alleles. Alternatively the mRNA detected may be decreased because it has a decreased half life as the result of a mutation or because it is not being expressed at its usual levels due to errors in the control of its transcription which may involve a positive feedback loop. The gene may also be entirely deleted from one (or possibly both) alleles.

If, in sequencing the HSC73 gene in malignant breast tissue and paired normal tissue, a conserved point mutation(s) is detected which

affects mRNA sequence(s), a synthetic oligonucleotide(s) specific to it can be prepared. The expression of HSC73 mRNA detected with each of these synthetic oligonucleotides is then correlated with diagnostic and prognostic data.

5                   Synthetic oligonucleotides may be prepared which are antisense to each of the three U14 SNURPS, for use in examining the expression of the three SNURPS in malignant tissue from all tissues. The expression of the three SNURPS detected using these synthetic oligonucleotides is then correlated with diagnostic and prognostic data.

10                   A synthetic oligonucleotide staining procedure for HSC73 mRNA expression will be of use in a routine histopathology laboratory for:

- Diagnosis of neoplasia (invasive and *in situ*)
- Prognosis of malignancy.
- Prognosis of *in situ* neoplasias such as DCIS/LCIS and CIN3.

15                   The pattern of expression of HSC73 protein and HSC73 mRNA in malignant disease largely parallels that of p53 and TP53 mRNA (29). Staining techniques similar to those for p53 and TP53 mRNA can be devised for HSC73 and HSC73 mRNA.

20    3)           DNA analysis

Sequence analysis of the HSC73 gene has revealed mutations as described above in malignant breast tissue and paired normal tissue shows no corresponding mutation.

                  A suitable method for detecting the numbers of copies of  
25   each HSC73 exon and each of the three SNURPS is as follows. At least two oligonucleotides, each labelled with a different detectable label, are provided. One oligonucleotide hybridises to a reference marker in the genome which is known not to be mutated in malignant disease. The second oligonucleotide hybridises to an exon of HSC73 or the three  
30   SNURPS. Comparison of the signals detected allows gene dosage measurements to be made for each exon of HSC73 and each of the

SNURPS. Gene dosage measurements are correlated with diagnostic and prognostic data. The detection systems that may be used include radiolabelled or fluorescence labelled oligonucleotide probes (including prompt [e.g. fluorescein] and time resolved fluorescence [lanthanide chelates like Europium and Samarium]) with or without a prior gene amplification (e.g. by PCR) step.

Detection of point mutations may also involve oligonucleotide hybridisation. The oligonucleotides used for these experiments will normally be very short, and will be specific for the mutation. They will be designed such that they will not hybridise to the published normal sequence of the gene under stringent conditions. Point mutations are correlated with diagnostic and prognostic data. Detection systems may be as already described.

Suitable methods to detect mutation also include technologies such as PCR amplification, cycle sequencing and Taqman™ PCR. Mutations will again be correlated with diagnostic and prognostic data.

Detection of mutations (such as deletions or point mutations) individually and in combination can be used for:

- Diagnosis of neoplasia (invasive and *in situ*)
- Prognosis of malignancy (invasive disease).
- Prognosis of *in situ* neoplasias.

Mutations within the HSC73 coding region of the genome may be germline and therefore transmitted through the population predisposing individuals to cancer (and possibly other disease).

#### 4) RNA analysis

Sequence analysis of the HSC73 mRNA in malignant breast tissue and paired normal tissue shows mutation. To date the majority of mutations in the HSC73 mRNA characterised are deletions in the HSC73 mRNA. Splice variation is also a possibility. All mutations detected will be correlated with diagnostic and prognostic data.



- 15 -

A suitable method for detecting the numbers of copies of each HSC73 exon expressed in the mRNA and each of the three SNURPS is similar to that described above under "DNA analysis". At least two oligonucleotides labelled with different detectable labels are provided.

5 Comparison of the signals detected allows RNA dosage measurements to be made for each exon of HSC73 and each of the SNURPS. mRNA dosage measurements are correlated with diagnostic and prognostic data. Detection systems may be as already described for the DNA analysis techniques.

10 Point mutations may be detected using short oligonucleotide probes specific for the mutation. The probes are designed such that they will not hybridise to the published normal sequence of the gene under stringent conditions. Point mutations will be correlated with diagnostic and prognostic data. Detection systems used may be as already described.

15 Suitable methods to detect mutations also include technologies such as PCR amplification, cycle sequencing and Taqman™ PCR. Mutations will again be correlated with diagnostic and prognostic data.

Detection of mutations in the mRNA or SNURPS (such as deletions or point mutations) individually and in combination may be used for:

- Diagnosis of neoplasia (invasive and *in situ*)
- Prognosis of malignancy (invasive disease).
- Prognosis of *in situ* neoplasias.

25

#### **Model Systems for Toxicity Testing**

A mouse carrying a hemizygous deletion of HSC73 and U14 SNURPS is a good model for carcinogenesis testing since:

- General house keeping is compromised.
- 30 - The HSC73 protein is expressed in every cell in the body (murine and human).

- 16 -

- HSC73/U14 SNURPS are mutated both at the RNA and protein level in many different human cancers.

A mouse carrying a hemizygous deletion of HSC73 and U14 SNURPS is susceptible to cancer in many ways:

- 5 - Increased mutation rate since there is reduced genome protection as a result of a reduced chaperone complement.
- Compromised centrosomes and cytokinesis compromise mitosis in general. HSC73 is an essential component of the centrosome.
- Steroid hormone activation is compromised leading to
- 10 aberrant inter and intra cell signalling and possible increased mitogenesis.
- Protein degradation in proteosomes is compromised since HSC73 is essential for the transport of a subset of proteins into the 28S proteosome.
- The correct functioning of all cell surface molecules is
- 15 compromised since HSC73 is essential for transport across membranes. Cells are therefore compromised in regard to self/self and self/antigen recognition.
- Ribosome biosynthesis and RNA processing are compromised since U14 SNURPS are essential for pre-ribosomal RNA
- 20 splicing. As a result translation is generally compromised.

A mouse carrying a hemizygous deletion of HSC73 and U14 SNURPS is a good model for carcinogenesis testing. The pathway to neoplastic disease promoted by a chemical in this animal may be detectable. As the hemizygous deletion of HSC73 and U14 SNURPS

25 knock out mouse is characterised with respect to development the compromised cellular pathways and functions will be distinguished. It should be possible to demonstrate that a chemical is a carcinogen in the hemizygous deletion of HSC73 and U14 SNURPS mouse model of carcinogenesis testing if for example it damaged the remaining steroid

30 hormone activation function to an extent which removed hepatocytes from normal growth control.

Manufacture of a mouse carrying a hemizygous deletion of HSC73 and U14 SNURPS.

5                   The cloning of murine HSC73 has been described previously (27,28).

                  Isolation of a 129/SvJ genomic BAC HSC73 clone requires PCR screening of the library with oligonucleotides which will not hybridise to processed pseudogenes elsewhere in the genome. The best  
10   oligonucleotides therefore span the U14 SNURPS which are in the introns of HSC73 in mouse and man. This provides three autonomous reactions with which to screen the library.

                  Isogenic targeting constructs are then prepared from the BAC clone for homologous recombination. In these clones the entire HSC73  
15   gene and associated SNURPS may be replaced by neomycin or another drug marker or the "normal" HSC73 may be replaced by a mutated copy and the drug marker inserted into the BAC elsewhere.

                  The homologous recombination HSC73 clone is electroporated into RW-4 embryonic stem cells and plated onto MEF feeder  
20   cells. Transformed embryonic stem cells are selected for by antibiotic selection, and a minimum of 150 clones are screened by Southern blotting and PCR for appropriate homologous recombination between the engineered target and the "normal" HSC73 locus in the 129/SvJ mouse genome. Recombinant clones are expanded and karyotyped. Those in  
25   which satisfactory recombination has occurred are used for either blastocyst injection or morula aggregation in order to generate chimeric mice. These will be used to obtain founder mice. The mice strains will be maintained by conventional breeding.

## EXAMPLES

### EXAMPLE 1

HSC73 expression in breast cancer was investigated by independent RNA in-situ hybridisation (RNA-ISH) and protein  
5 immunohistochemical (IHC) analysis of 8 non-malignant (3 fibrocystic change, 5 fibroadenomas) and 44 invasive breast cancer cases.

On in-situ analysis, HSC73 RNA was expressed at a high level (RNA-ISH score 5/5) in all normal tissues examined (breast acini, lymphocytes, endothelium, skin). This was associated with moderate  
10 tissue levels of the HSC73 protein (IHC score 3/5). Assay of the 8 non malignant breast lesions revealed a similar uniform intense staining of HSC73 RNA in the lesional cells and adjacent histologically normal breast acini (RNA-ISH score 5/5). Increased protein staining (IHC score 4/5) was seen in 3 of 5 fibroadenomas (60%) and focally in the 3 fibrocystic samples  
15 (apocrine metaplastic cells only) (Figure 1.1A and B). As expected of a constitutive 'housekeeping' gene, the ~2.3kb HSC73 mRNA transcript is uniformly expressed in many normal tissues (Figure 3 a).

Of 44 archival breast cancers (and adjoining normal acini) analysed, 32 cases (73%) showed a moderate/marked reduction in HSC73  
20 mRNA expression (RNA-ISH score 1-3/5), and 31 of these (70% of total) had increased expression of the HSC73 protein (IHC score 4-5/5) (Figure 2.3 A and B). Tumour infiltrating macrophages and lymphocytes had high levels of both HSC73 RNA and protein. Metastatic tumours from the same cases showed the inverse relationship between mRNA and protein  
25 strikingly, with near total absence of the HSC73 RNA and elevated HSC73 protein (Figure 2.4 A and B). In a series of over 40 cases of pure ductal carcinoma in situ (DCIS), ~50% have this inverse microscopic pattern of RNA and protein expression (Figure 2.2 A and B) (NCAH *et al*, m/s in preparation). This possibly indicated a biologically important difference  
30 between malignant and non-malignant cells in the HSC73 gene products.

18 cases (and adjacent normal tissue) from the above series,

with material for RNA and DNA analysis, were subsequently used to independently assess gene structure (9 cases also had sufficient tissue for Western blotting): Aberrant bands were visualised in 8 of 18 tumours (44%) on northern blots (the gene has no splice variants described), indicating that they comprised a significant fraction of the HSC73 RNA (Figure 3 b). Of the 18, 12 cases (67%) had intra-exon breakpoints (sites at which a deletion in the mRNA has occurred) in the HSC73 gene by RT-PCR sequencing (in 3 normal lanes, aberrant RT-PCR bands were present; 2 were aberrantly spliced at exon-intron boundaries with exons deleted, and one with an intra-exon breakpoint actually had residual tumour) (Figure 3 c). Further, Western blots showed aberrant truncated protein in 7 of the 9 cases, evidence that the mutant RNA is translated to abnormal protein (Figure 3 e). Given the highly conserved nature of the HSP70 gene family (especially at the N-terminal end of HSC73), the probes used for RNA, protein and DNA analysis could not span the complete sequence, necessarily limiting mutation detection and data overlap from different analytic methods. Nonetheless, all cases with truncated bands on Northern blots had RT-PCR mutations, and where no aberrant band was detected by Northern analysis and RT-PCR, no aberrant bands were detected by Western blotting.

Analysis of 8 breast cancer (and one mononuclear) cell lines was performed at RNA, DNA and protein level. Northern analysis revealed aberrant transcripts in MDA-MB435, MDA-MB468 and the U937 ('macrophage') cell lines (Table below). No mutations were detected in MDA-MB157, MDA-MB231, MDA-MB361, MDA-MB453, SKBR3 or T47D (data not shown). Mutations in MDA-MB435, MDA-MB468 and U937 were seen by RT-PCR (Figure 3 d) and sequenced. Western blot analysis demonstrated a truncated HSC73 isoform in the U937 line (Figure 3 f).

To summarise, aberrant inverted patterns of HSC73 mRNA and protein expression occurred in 31 of 44 (70%) invasive breast cancers. Aberrant HSC73 bands were also detected on Northern blots (44%) and

- 20 -

RT-PCR (67%). Sequencing revealed intra-exon breakpoints in most of the truncated tumour RNA, while Western blots and IHC showed aberrant protein expression patterns and mutation, with over-expression of wild-type (Wt) band and the presence of multiple truncated mutant (Mt) bands.

5 Mutations in the DNA have been discovered as described above.

Results are displayed in the following table and in Figures 2 and 3.

TABLE

Case	Northern	RT-PCR breakpoint(s)	Location of breakpoints	RNA-ISH (N score = 5)	IHC (N score = 3)
16	Mt	1114-4712	Exon 2 - 3' untranslated	4	4-5
70	Mt	1046-4714	Exon 3 - 3' untranslated	4	4-5
22	Mt	1593-4683	Exon 3 - 3' untranslated	3	5
24	Mt	1117-4763	Exon 2 - 3' untranslated	2-3	4-5
34	Mt	1158-4751	Exon 2 - 3' untranslated	2-3	4-5
38	Wt	1595-4716	Exon 3 - 3' untranslated	3	5
54	Mt	1085-4688, 1639-4608	Exon 2 - 3' untranslated, Exon 3 - Exon 9	2	5
58	Wt	1166-4725, 2826-4628	Exon 2 - 3' untranslated Exon 5 - 3' untranslated	1-2	4-5
20	Mt	1639-4608	Exon 3 - Exon 9	3	4
52	Wt	1163-4751	Exon 2 - 3' untranslated	3	4-5
62*	Wt	1648-4688	Exon 3 - 3' untranslated	3	4-5
64	Mt	1038-4715	Exon 2 - 3' untranslated	3-4	5
66	Wt	-	-	3-4	4-5
60	Wt	-	-	3-4	4-5
26	Wt	-	-	5	3
36	Wt	-	-	5	3
50	Wt	-	-	5	3
72	Wt	-	-	5	3
MDA-MB435	Mt	1191-4753	Exon 2 - 3' untranslated	-	-
MDA-MB468	Mt	Splice variant	Exon 2 - Exon 9	-	-
U937	Mt	2185-4648	Exon 4 - 3' untranslated	-	-

10 The table shows deduced HSC73 gene structure and  
expression data for the 18 fresh cases, with mutated cell lines listed below.  
N= normal; Nd=not determined; Mt=mutation; Wt=wild type. \* tumour with  
microscopic invasion into adjacent 'normal'. Note that all aberrant bands  
were not completely sequenced once a breakpoint was determined. Larger  
15 deletions are thus over-represented.

**Methods:****HSC73 mapping**

A contiguous chromosome 11q22-qterm YAC library plated in  
5 an ordered array was hybridised to oligonucleotides specific for HSC73,  
localised to an 11q23.3 YAC (y667F08) between D11S1336 and  
D11S1284 (11.7cR; ~500kb) and confirmed by PCR and southern analysis  
(data not shown).

**Cases**

44 archival paraffin embedded blocks of sporadic breast  
cancer and paired normal tissue were serially sectioned and analysed. Of  
these, 18 cases had frozen tissue for RNA, DNA and protein (9 cases)  
extraction.

15

**RNA analysis:**

RNA-ISH: sections were dewaxed, rehydrated, proteinase K digested  
(1mg/ml in 2mM CaCl<sub>2</sub>, 10mM Tris, pH 7.4) for 30min at 37°C and  
hybridised overnight at 37°C in 50% deionised formamide, 2X SSC, 20%  
20 dextran sulphate, 100mM antisense probe  
(5' CATTCTCCTGGCATGCCTCCTGCACT-3' [SEQ ID NO: 1]),  
digoxigenin labelled (Boehringer). Sections were washed in TBS, pH 7.6,  
0.1% Triton X-100, blocked (TBS, pH 7.6, 0.1% Triton X-100, 3% BSA,  
20% goat serum), incubated with 1: 500 alkaline phosphatase conjugated  
25 anti-digoxigenin antibody (Boehringer) for 30 mins and washed again in  
TBS (pH 7.6, then pH 9.0) for 5 mins. Signal was developed in 100mM  
Tris, pH 9.0, 50mM MgCl<sub>2</sub>, 100mM NaCl, 330mg/ml nitroblue tetrazolium  
(NBT), 165mg/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and 1mM  
levamisole for up to 30 mins. Control sections included a complementary  
30 sense probe, RNase pre-treatment and competitive signal attenuation by  
unlabelled antisense probe.

- 22 -

*Northern:* 20mg total RNA was resolved on 1.5% agarose-3% formaldehyde gels, integrity visualised by ethidium bromide, blotted to Hybond N+ (Amersham) and hybridised overnight to a  $\alpha^{32}\text{P}$  labelled cDNA probe from exon 5-3' polydenylation site (ATCC IB743), in 50% formamide, 0.75M NaCl, 36mM  $\text{Na}_2\text{HPO}_4$ , 4mM  $\text{NaH}_2\text{PO}_4$ , 0.15M Tris-HCl, pH 8.0, 10mM EDTA, 5X Denhardts, 200 $\mu\text{g}/\text{ml}$  denatured salmon sperm DNA and 0.5% SDS (w/v) at 42°C. Washes were for 15 min in 2X SSC, 0.1% SDS; 0.5X SSC, 0.1% SDS and up to 4 times in 0.1X SSC, 0.1% SDS at 65°C and autoradiographed on Xomat-MS film (Kodak) at -70°C for up to 7 days. Multiple-tissue northern were purchased (Clontech) and probed as above.

*RT-PCR and cDNA sequencing:* 10 $\mu\text{g}$  total RNA was incubated with 10units RNase-free DNase I (Boehringer) at 37°C for 45 min, twice phenol-chloroform extracted and ethanol precipitated. cDNA was transcribed by SuperScript II RNase H<sup>-</sup> reverse transcriptase (Life Technologies) with the HSC73 specific primer (5' AAGACATTGCATTTTCCACTTACAATA 3' [SEQ ID NO:2]). 1.5 $\mu\text{l}$  cDNA was used in 35 cycles of hot-start PCR using 10pmoles of primers P1 (5' TTGTGGCTTCCTTCGTTA 3' [SEQ ID NO:3]) and P2 (5' CAGTGTATAAAGTGCAATG 3' [SEQ ID NO:4]) in 200 $\mu\text{M}$  dNTPs, 1.5mM  $\text{Mg}(\text{OAc})_2$ , 1X XL PCR buffer (Perkin-Elmer) and 0.5 units of rTth XL Taq (Perkin-Elmer) in a 25 $\mu\text{l}$  reaction on a Perkin Elmer 9600 cycler at 94°C denaturation for 0.25 min, 54°C annealing for 0.25 min and 72°C extension for 1.25-2.75 min. 1 $\mu\text{l}$  of 1:50 PCR products were used in 35 cycles of another hot-start PCR with 10pmoles of the nested primers P3 (5' TTGGAGCCAGGCCTACAC 3' [SEQ ID NO:5]) and P4 (5' CCTTCCCCTGTGCATATG 3' [SEQ ID NO: 6]) in 200 $\mu\text{M}$  dNTPs, 3mM  $\text{MgCl}_2$ , 50mM KCl, 10mM Tris-HCl (pH 7.5), 0.1% Triton X-100 and 0.5 units SuperTaq (HT Biotechnology, UK) in a 25 $\mu\text{l}$  reaction, cycled similarly with annealing and extension at 65°C and 70°C respectively. PCR products were visualised on 1% agarose gels. Control RT negative samples were blank. DNA fragments were excised, purified with a QIA



- 23 -

quick kit (Qiagen),  $\alpha^{35}\text{S}$  cycle sequenced by the Amplicycle kit (Perkin Elmer) with each inner primer for 25-30 cycles, resolved on 6% denaturing urea-polyacrylamide gels and visualised on Xomat-AR film (Kodak).

## 5 DNA analysis

*Southern*s: 20 $\mu\text{g}$  DNA incubated with *Bam*H1 and *Bg*/II (MBI Fermentas) was resolved on 0.8% agarose gels, filters hybridised to  $\alpha^{32}\text{P}$  labelled probes subcloned into pGEM (5' probe: PCR generated 700bp intron 1 fragment; 3'probe: 700bp exon 8-3'untranslated) in 50% formamide buffer  
10 at 42°C o/n, washed at 65°C in 0.1X SSC, 1% SDS twice for 20 minutes and visualised on Xomat-AR film (Kodak) overnight at -70°C. The 5' probe yielded a single 8.4 kb band, consistent with a single copy of HSC73 in the genome. The 3' probe yielded 7 bands, identifying HSC73 and family members.

15 *PCR*: 50ng RNaseA treated DNA was used to amplify ~3.8kb of the HSC73 genomic sequence (intron 1-3' untranslated) by 42 cycles of hot-start PCR with 15pmoles of the primers P5 (5':  
TGGTTAAGTGTCTGTTAAG 3' [SEQ ID NO: 7]) and P6 (5'  
20 CAATTGTATGGTGCCAATTT 3' [SEQ ID NO: 8]) in 200 $\mu\text{M}$  dNTPs, 1.5mM  $\text{MgCl}_2$ , 50mM KCl, 10mM Tris-HCl (pH 8.0), 0.1% Triton X-100 and 0.5units SuperTaq (HT Biotechnology, UK) in a 25 $\mu\text{l}$  reaction at 94°C denaturation for 0.25 min, 56°C annealing for 0.25 min and 70°C extension for 2.5-4 min. PCR products were visualised on 0.7% agarose gels.

25

## Protein analysis

*Immunohistochemistry*: Sections were dewaxed, rehydrated, pressure cooked for antigen retrieval (1.5 mins at maximum pressure; 10mM sodium citrate buffer, pH 6.0), incubated with a goat polyclonal antibody (Santa  
30 Cruz, USA) against HSC 73 amino acids 583-601, at 1:200 dilution in PBS/BSA for 60 minutes at 37°C. Secondary incubation used a

- 24 -

biotinylated anti-goat antibody (DAKO) followed by a standard avidin-biotin complex (ABC, DAKO) for 30 minutes and developed with DAB.

Western *Blots*: 10µm cryosections were boiled in 24 mM Tris-HCl, pH 6.8, 4% SDS (w/v), 10% β-mercaptoethanol, 20% glycerol for 10 mins, sonicated, debris pelleted and protein estimated (Bio-Rad). 10µg protein was resolved on 10% polyacrylamide gels, electroblotted onto Hybond C+ (Amersham), blocked (5% (w/v) milk powder in 1X TBS, 0.1% Tween 20), treated with the HSC73 antibody (1:2000) and washed in 1X TBS, 0.1% Tween 20 (v/v). The membrane was incubated in horse radish peroxidase conjugated anti-goat antibody (1:500) (DAKO), washed in 1X TBS, 0.1% Tween 20 (v/v) and developed by ECL (Amersham). Coomassie Brilliant Blue gel staining and a monoclonal antibody against CD68 (KP1) controlled for protein integrity.

## **EXAMPLE 2**

### **Sequence analysis of exon 3.**

Analyses of cell lines and clinical material have revealed mutations including base pair substitutions or point mutations in exon 3 and a two base pair deletion in intron 2. Of 14 tumours, 3 (21%) had point mutations which changed the coding sequence of exon 3 (adjacent normal breast did not have the same mutation). These three cases were all ones in which aberrant splicing was previously detected. Of the three tumours in which point mutations were identified, two were also homozygous and one heterozygous for a 2bp germline deletion in intron 2 adjacent to exon 3. In total, 15% of breast tumours were heterozygous and 15% homozygous for the intron 2 deletion. The intron 2 deletion has not been identified in tumours in which there was no aberrant splicing.

However, blood sampled from 21 women who developed benign breast disease and 12 women who developed malignant breast disease was heterozygous for the intron 2 polymorphism in 30% of each

group.

The polymorphism in intron 2 of the gene may cause susceptibility to aberrant splicing of *HSC73* in malignant cells; additional factors must be involved since aberrant transcripts have not been observed  
5 in normal breast. RNA truncations could occur if cryptic splice sites are produced or if mutated (and/or polymorphic) pre-mRNA primary structure affects tertiary structure bringing incorrect sequences into contact which may be spliced together. The U14 SNURPs which are transcribed via an intron processing pathway concurrent with *HSC73* mRNA splicing, and the  
10 repetitive nature of the intron/exon structure, may make *HSC73* pre-mRNA splicing inherently susceptible to incorrect splicing in a malignant cell.

The point mutations we have detected in exon 3 of the human tumours which change coding are:

Valine 83 is changed to alanine  
15 gtc is changed to gcc

Glycine 99 is changed to Serine  
ggc is changed to agc

20 Tyrosine 107 is changed to histidine  
tac is changed to cac

The polymorphism in intron 2 is:  
aaagtgtttcattgacacctttacagAT  
25 which becomes  
aaagtgtttcattgacacctttacagAT  
where AT is the start of exon 3  
the sequence changes 23bp upstream of exon 3.

**EXAMPLE 3****Transfection Studies on HSC73**

Functional studies were performed using mda-mb435, a breast cancer cell line known to have aberrant hsc73 mRNA, as a model.

5 The HSC73 gene was transfected into the cell line. Three stable subclones of this cell line expressing normal hsc73 from a genomic clone were produced and investigated for *in vitro* and *in vivo* tumour formation in mouse models. Western blotting confirmed increased full length hsc73 protein in all three subcloned cell lines. The clones were each introduced  
10 into three test animals. There were three control animals injected with untransfected cells of a breast cancer cell line. Proliferation assays demonstrated that expression of wild type hsc73 in the mda-mb435 cell lines decreases the rate of cell growth both *in vitro* and *in vivo* in nude athymic mice. *In vitro* proliferation rates for the three stable hsc73  
15 expressing subclones and appropriate control cell lines were measured. The stable transfectants divide at approximately 1/4 of the rate of division of the wild type cell line (data not shown). *In vivo* proliferation assays showed that 500,000 transfected cells produced no tumours in nude mice (except in a single case) while the wild type mda-mb435 produced tumours in 100%  
20 of cases (Figure 7). It is likely that in the case where tumours did develop from the transfected cells, the HSC73 gene was for some reason no longer being expressed (see figure legend).

In a similar *in vivo* experiment the procedure described was repeated except that  $2 \times 10^6$  cells were injected into each animal and control  
25 transfectants expressing the hygromycin resistance gene without HSC73 were included. In all nine mice injected with the stable transfectants (i.e. three mice for each of the three clones) there was no tumour formation. In the hygromycin resistance gene control mice, tumour formation was at the same level as for the mice injected with the wild type cell line.

30 These results demonstrate that hsc73 can suppress tumour formation. hsc73 expressed in certain breast cells can reduce their

proliferation. There are two likely biochemical explanations for these observations.

1. Mutation in hsc73 prevents apoptosis in breast carcinoma cells. Replacement of hsc73 function in the mda-md435 following stable transfection repairs the apoptotic function and gross proliferation of the cells is therefore reduced. Examples of biochemical defects could include the degradation of c-fos in the 26S proteasome, a known early reaction in the cascade for the activation of caspase 3 by caspase 9 and cytochrome c. Other explanations include the correct cellular localisation of apoptosis related proteins such as BAG and BIZ.
2. mda-mb435 expressing normal hsc73 could be stalled in a stage of their cell cycle progression. The cell line could have impaired wild type hsc73 function as a means of overcoming such a cell cycle block. Obvious classes of molecules to examine for their stability and localisation in the cell lines include cyclins and cdk inhibitors.

Given the pleiotrophism of this gene it may well be that both mechanisms play a role in suppressing malignancy in the wild type protein.

#### Figure Legends:

- Figure 2-** Paired serial sections of breast lesions stained for IHC (panel A) and RNA-ISH (panel B). Normal/non-malignant cells (◀) and malignant cells (◀) are indicated. (1) The fibroadenoma shows intense signal in epithelial cells on both analyses. (2) DCIS shows increased tumour cell HSC73 protein but low RNA compared to normal acini. (3) Invasive breast cancer cells show a similar phenomenon, with compressed normal ducts staining weakly for protein but intensely for RNA, compared to tumour cells with the opposite pattern. (4) Metastatic tumour in the lymph node stains highly for protein while RNA signal is virtually absent, contrasting sharply with the surrounding normal lymphocytes. Scale bar = 100µm.

**Figure 3- a)** Multiple tissue northern blot (l-r: spleen, thymus, prostate,

- 28 -

testis, ovary, small intestine, colon, leucocyte) probed with 1.1kb cDNA probe (with  $\beta$ -actin control panel below) shows uniform expression of HSC73. b) Northern of paired normal (N) and tumour (T) samples (l-r: tumour cases 16, 20, 34, 26, 22) and cell lines MDA-MB435 (1), MDA-MB468 (3) and U937 (5) are shown with aberrant transcripts indicated (◀). c) HSC73 RT-PCR samples (l-r: tumour cases 20, 64, 54, 24, 22, 62, 58, 26, 34) with multiple aberrant bands in tumour lanes (N\* indicates a 'normal' lane with aberrant transcript, subsequently shown to have tumour cells on cryosection). d) HSC73 RT-PCR of the cell lines, showing aberrant bands in MDA-MB435, MDA-MB468 and U937, but not in MDA-MB453 or T47D. e) Western blot of paired cases (N/T) run as RT-PCR samples above, probed with polyclonal antibody to HSC73 N-terminal peptides, show aberrant protein bands in 7 of the 9 tumour lanes. f) Western blot with the cell lines MDA-MB453 (2) and T47D (4) in addition to those above, shows a truncated HSC73 isoform in U937.

**Figure 4- a)** Genomic and mRNA structure of HSC73 showing the localisation of the probes (black bars) and PCR primers (arrows) used. The upper genomic structure has 9 exons (coding exons: stippled boxes; non-coding regions of exons: stippled/black boxes). The dashed introns (5, 6 and 8) contain the U14 SNURPS. Note the antibody epitope (=) and RNA-ISH probe (-) sites on HSC73 mRNA.

**Figure 5-** Human HSC73 gene and amino acid sequence (Y00371)

**Figure 6 -** Murine HSC73 cDNA and amino acid sequence (U27129)

**Figure 7-** Three BALB/c nude mice were injected subcutaneously with 500,000 cells from each cell line. After six weeks the mice were sacrificed and tumours evaluated.

Lane 1: mda435 parental line (tumour weights 8, 30 and 18mg)

- 29 -

Lane 2: mda435 HSC73 transfectant 1 (no tumours)

Lane 3: mda435 HSC73 transfectant 2 (one tumour of 68mg)

Lane 4: mda435 HSC73 transfectant 3 (no tumours)

Notes. The tumour which grew in one mouse injected with mda435

- 5 HSC73 transfectant 2 is thought to have arisen from a cell which had deleted the transfected clone. In the mice the cells are no longer under selection.

### References

- 10 1. Stickland, J.E., Tomlinson, I.P.M., Lee, A.S.G., Evans, M.F. and McGee, J.O. (1992). Allele loss on chromosome 11q is a frequent event in breast cancer (abstract). *Br. J. Cancer*, **66**, (Suppl 17), 3.
2. Tomlinson, I.P., Stickland, J.E., Lee ASG, Bromley L, Evans M.F., Morton J. and McGee, J.O. (1995). *J. Clin Pathol.*, **48**, 424-428
- 15 3. Koreth, J., Bethwaite, P.B. and McGee, J.O. (1995). Mutation at chromosome 11q23 in human nonfamilial breast cancer: a microdissection analysis. *J. Pathol.*, **176**, 11-18.
4. Koreth, J., Bakkenist, C.J. and McGee, J.O. (1997). Allelic deletions at chromosome 11q22-q23.1 and 11q25-qterm are frequent in
- 20 sporadic breast but not colorectal cancers. *Oncogene*, **14**, 431-437
5. Negrini, M., Sabbioni, S., Possati, L., Rattan, S., Corallini, A., Barbanti, B.G. and Croce, C.M. (1994). Suppression of tumorigenicity of breast cancer cells by microcell-mediated chromosome transfer: studies on chromosomes 6 and 11. *Cancer Res.*, **54**, 1331-1336.
- 25 6. Hampton, G.M., Mannermaa, A., Winqvist, R., Alavaikko, M., Blanco, G., Taskinen, P.J., Kiviniemi, H., Newsham, I., Cavenee, W.K. and Evans, G.A. (1994). Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. *Cancer Res.*, **54**, 4586-4589.

7. Bethwaite, P.B., Koreth, J., Herrington, C.S. and McGee, J.O. (1995). Loss of heterozygosity occurs at the D11S29 locus on chromosome 11q23 in invasive cervical carcinoma. *Br. J. Cancer*, **71**, 814-818.
8. Tomlinson, I.P., Gammack, A.J., Stickland, J.E., Mann, G.J.,  
5 MacKie, R.M., Kefford, R.F. and McGee, J.O. (1993). Loss of heterozygosity in malignant melanoma at loci on chromosome 11 and 17 implicated in the pathogenesis of other cancers. *Genes Chrom. Cancer*, **7**, 169-172.
9. Evans, M.E., Herrington, C.S., Koreth, J., Bakkenist, C.J. and  
10 McGee, J.O. (1997). Evidence for clonality and loss of heterozygosity at 11q23 in CIN III lesions. (manuscript in preparation).
10. Foulkes, W.D., Campbell, I.G., Stamp, G.W. and Trowsdale, J. (1993). Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. *Br. J. Cancer*, **67**, 268-273.
- 15 11. Baffa, R., Negrini, M., Mandes, B., Rugge, M., Ranzani, G., Hirohashi, S. and Croce, C.M. (1996). Loss of heterozygosity for chromosome 11 in adenocarcinoma of the stomach. *Cancer Res.*, **56**, 268-273.
12. Rasio, D., Negrini, M., Manenti, G., Dragani, T.A. and Croce,  
20 C.M. (1995). Loss of heterozygosity at chromosome 11q in lung adenocarcinoma: identification of three independent regions. *Cancer Res.*, **55**, 3988-3991.
13. Koreth, J., Bakkenist, C.J. and McGee, J.O. (1997). Chromosome 11 and cancer: a review. (manuscript in preparation).
- 25 14. Trent J., Yang, J.-M., Emerson, J., Dalton, W., McGee, D., Massey, K., Thompson, F. and Villar, H. (1993). Clonal chromosome abnormalities in human breast carcinomas. II. Thirty-four cases with metastatic disease. *Genes Chrom. Cancer*, **7**, 194-203.
15. Herrington, C.S., Leek, R.D. and McGee, J.O'D. (1995).  
30 Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes. *J. Pathol.* **176**, 353-359.



16. Saxon, P.J., Srivatsan, E.S. and Stanbridge, E.J. (1986). Introduction of human chromosome 11 via microcell transfer controls tumorigenic expression of HeLa cells. *EMBOJ.*, **5**, 3461-3466.
17. Parshad, R., Price, F.M., Oshimura, M., Barrett, J.C., Satoh, H., Weissman, B.E., Stanbridge, E.J. and Sanford, K.K. (1992). Complementation of a DNA repair deficiency in six human tumor cell lines by chromosome 11. *Hum. Genet.*, **88**, 524-528.
18. Robertson, G., Coleman, A. and Tracey, G.L. (1996). A malignant melanoma tumor suppressor on human chromosome 11. *Cancer Res.*, **56**, 4487-4490.
19. Phillips, K.K., Welch, D.R., Miele, M.E., Lee, J-H., Wei, L.L. and Weissman, B.E. (1996). Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11. *Cancer Res.*, **56**, 1222-1227.
20. Dworniczak, B., Mirault, M.E. (1987). Structure and expression of a human gene coding for a 71kd heat shock 'cognate' protein. *Nuc. Acids Res.* **15**, 5181-5197.
21. Tavaria, M., Gabriele, T., Anderson, R.L., Mirault, M-E, Baker, E., Sutherland, G. and Kola, I. (1995). Localization of the gene encoding the human heat shock cognate protein, HSP73, to chromosome 11. *Genomics* **29**, 266-268.
22. Brown, R.C., Hong-Brown, L.Q., Doxsey, S.J., Welch, W.J. (1996). Molecular Chaperones and the Centrosome. *J. Biol. Chem.* **271**, 833-840.
23. Brown, R.C., Martin, R.L., Hansen, W.J., Beckmann, R.P., Welch, W.J. (1993). The constitutive and stress inducible forms of hsp70 exhibit functional similarities and interact with one another in an ATP dependent fashion. *J. Cell Biol.* **120**, 1101-1112.
24. Bercovich, B., Stancovski, I., Mayer, A., Blumfield, N., Laszlo, A., Schwartz, A.L., Ciechanover, A. (1997). Ubiquitin-dependent

- Degradation of Certain Protein Substrates in Vitro Requires the molecular Chaperone Hsc70. *J. Biol. Chem.* **272**, 9002-9010.
25. Brodsky, J.L. (1996). Post-translational protein translocation: not all hsc70s are created equal. *TIBS* **21**, 122-126.
- 5 26. Barbhaiya, H., Leverette, R., Liu, J., Maxwell, E.S. (1994). Processing of U14 small nucleolar RNA from three different introns of the mouse 70kDa-cognate-heat-shock-protein pre-messenger RNA. *Eur. J. Biochem.* **226**, 765-771.
27. Giebel, L.B., Dworniczak, B.P., and Bautz, E.K.F. (1988).  
10 Developmental regulation of a constitutively expressed mouse mRNA encoding 72kDa heat shock-like protein. *Dev. Biol.* **125**, 200-207.
28. Soulier, S., Vilotte, J-L., L'Huillier, J. and Mercier, J-C. (1996). Developmental regulation of murine integrin B1 subunit- and HSC73-  
encoding genes in mammary gland: sequence of a new mouse HSC73  
15 cDNA. *Gene* **172**, 285-289.
29. Harris, A.L. (1992). p53 expression in human breast cancer. *Adv. Cancer Res.* **59**, 69-88.
30. Koonin, E.V. and Abagyan, R.A.. (1997). TSG101 may be the  
prototype of a class of dominant negative ubiquitin regulators. *Nat. Genet.*  
20 **16**, 330-31.
31. Haber, D. and Harlow, E. (1997). Tumour suppressor genes: evolving definitions in the genomic age. *Nat. Genet.* **16**, 320-22.
32. O'Malley, K., Mauron, A., Brachas, J.D. and Kedes, L. (1985). Constitutively expressed rat mRNA encoding a 70-kilodalton heat-shock-  
25 like protein. *Mol. Cell Biol.* **5**, 3476-83.
33. Trinh, R.Q. and Maxwell, E.S. (1988). Homologous genes for mouse 4.5S hybRNA are found in all eukaryotes and their low molecular weight RNA transcripts intermolecularly hybridize with eukaryotic 18S ribosomal RNAs. *Nucleic Acids Res.* **16**, 6041-56.
- 30 34. Sager, R. (1997). Expression genetics in cancer: shifting the focus from DNA to RNA. *Proc. Natl. Acad. Sci. U S A* **94**, 952-5.

35. Rice, L.W., Jazaeri, A.A. and Shupnik, M.A. (1997). Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. *Gynecol. Oncol.* **65**, 149-57.
36. Zhang, Q.X., Hilsenbeck, S.G., Fuqua, S.A. and Borg, A.  
5 (1996). Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. *J. Steroid Biochem. Mol. Biol.* **59**, 251-60.

## CLAIMS

1. A method of diagnosis performed on a biological sample, which method comprises detecting the aberrant expression of a gene at the HSC73 locus, or detecting a mutation at the HSC73 locus, in the sample.
2. The method according to claim 1, for diagnosing neoplasia or a susceptibility to neoplasia.
3. The method according to claim 1 or claim 2, wherein detection is at the protein level.
4. The method according to claim 3, wherein the amount of HSC73 protein is detected by means of an antibody specific for HSC73.
5. The method according to claim 4, wherein the antibody is specific for an epitope encoded by a region of the HSC73 gene which bridges exons 8 and 9.
6. The method according to claim 1 or claim 2, wherein detection is at the DNA or RNA level.
7. The method according to claim 6, wherein HSC73 DNA or RNA is detected by means of a specific probe.
8. The method according claim 6 or claim 7, wherein an abnormality in exon 2 or exon 3 is detected.
9. The method according to claim 8, wherein the abnormality is a deletion in intron 2.
10. The method according to claim 8, wherein the abnormality is a point mutation in exon 3.
11. The method according to any one of claims 1 to 10, wherein the biological sample is derived from breast, ovary, prostate or lung tissue.
12. A DNA which encodes a mutated or unusual polymorphic form of an HSC73 mRNA or polypeptide, fragments of the DNA including the mutation or polymorphism and complementary DNAs.
13. The DNA according to claim 12, containing an abnormality in at least one of intron 2 and exon 3.

- 35 -

14. An RNA molecule encoded by the DNA according to claim 12 or claim 13.
15. A polypeptide encoded by the DNA according to claim 12 or claim 13.
- 5 16. Oligonucleotides capable of specifically hybridising with a region of an HSC73 DNA or RNA according to any one of claims 12 to 14, which region includes the mutation or polymorphism.
17. The oligonucleotides according to claim 16, labelled with a detectable moiety.
- 10 18. Antibodies which bind specifically to a region of an HSC73 protein encoded by exon 3.
19. The antibodies according to claim 18, wherein the exon 3 is a mutated or unusual polymorphic form of HSC73 exon 3.
20. Synthetic peptides for use in raising antibodies according to claim 18 or claim 19.
- 15 21. A genetically modified non-human mammal having genetic weakness to disease, in which the somatic cells and germ cells have at least one mutated or deleted copy of HSC73.
22. An embryonic stem cell transformed with a nucleic acid capable of replacing a copy of HSC73 in the cell.
- 20 23. A cell line genetically engineered to have at least one mutated or deleted copy of HSC73.
24. A kit comprising an oligonucleotide according to claims 16 or 17 or an antibody according to claims 18 or 19.
- 25 25. A composition comprising a gene delivery vector which comprises a nucleic acid encoding an HSC73 protein under the control of a suitable promoter, together with a pharmaceutically acceptable carrier.
26. A method of treatment comprising introducing into a patient at least one copy of a nucleic acid which encodes a native HSC73 under the control of a suitable promoter.
- 30

Fig.1.




Fig.2.




Fig.3.







Fig.4.



5/9

Figure 5

Key	Location/Qualifiers
source	1..5408 /organism="Homo sapiens" /clone="phage521" /clone_lib="human liver DNA in lambda L47.1"
misc_feature	4..17 /note="heat shock consensus element"
misc_feature	109..113 /note="regulatory sequence"
misc_feature	178..191 /note="heat shock consensus element"
TATA_signal	199..203
prim_transcript	227..>4630
mRNA	join(227..304,1035..1244,1567..1772,2097..2249,2337..2892, 3104..3306,3535..3733,3881..4113,4445..>4630)
exon	227..304 /number=1
intron	305..1034 /number=1
exon	1035..1244 /number=2
CDS	join(1040..1244,1567..1772,2097..2249,2337..2892, 3104..3306,3535..3733,3881..4113,4445..4630) /db_xref="PID:g32467" /db_xref="SWISS-PROT:P11142" /product="71 Kd heat shock cognate protein" /translation="MSKGPAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFT DTERLIGDAAKNQVAMNPTNTVFDKRLIGRRFDDAVVQSDMKHWPFMVVNDAGRPKVQ VEYKGETKSFYPEEVSSMVLTKMKEIAEAYLGKTVTNAVVTVPAYFNDSQRQATKDAGT IAGLNLVRIINEPTAAAIAYGLDKKVGAEARNVLI FDLGGGTFDVSILTIEDGIFEVKST AGDTHLGGEDFDNRMVNHFAIEFKRKHKKDI SENKRAVRLRTACERAKRTLSSSTQAS IEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDIVLVGGS TRIPKIQKLLQDFNGKELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLLLDVTPL SLGIETAGGVMTVLIKRNTTIPTKQTQFTTYSNQPGLVLIQVYEGERAMTKDNNLLGK FELTGIPAPRGVPQIEVTFDIDANGILNVS AVDKSTGKENKITITNDKGRLSKEDIER MVQEAEEKYKADEKQQRDKVSSKNSLESYAFNMKATVEDEKLQKINDEDKQKILDKCNE IINWLDKNQTAEKEEFHQKELEKVCNPIITKLYQSAGGMPGGMPGGFPGGGAPPSGG ASSGPTIEEVD"
intron	1245..1566 /number=2
exon	1567..1772 /number=3
intron	1773..2096 /number=3
exon	2097..2249 /number=4
intron	2250..2336 /number=4
exon	2337..2892 /number=5
intron	2893..3103 /number=5
exon	3104..3306 /number=6

intron 3307..3534  
/number=6  
exon 3535..3733  
/number=7  
intron 3734..3880  
/number=7  
exon 3881..4113  
/number=8  
intron 4114..4444  
/number=8  
exon 4445..>4630  
/number=9  
polyA\_signal 4843..4848

Sequence 5408 BP; 1411 A; 1079 C; 1420 G; 1498 T; 0 other;

GAGCTTGA	AA	GTTCCAGA	AA	GCTGCGGT	G	GTGCGTTAT	C	GTGAGGCGG	C	GCGGTGGGGT	60
GGGTGCGG	AA	GGGGGCGAG	G	CGAGGAGTG	G	AGCCGCGTT	G	TGATTGTGAT	T	TGGGTCTTGT	120
AAGGGCAG	CC	GGACTCTAT	T	GGCCGGGA	AA	CTAATGCAG	G	AAGCAGGCG	G	ACCCCTTCTG	180
GAAGGTTCT	A	AGATAGGGT	A	TAAGAGGC	A	GGTGGCGGG	C	GGAAACCGG	T	GCTCAGTTGA	240
ACTGCGCTG	C	AGCTCTTGG	T	TTTTTGTGG	C	TTCTTCGTT	T	ATTGGAGCC	A	GGCCTACACC	300
CCAGGTAAAA		CCTCTGCTC	A	AGAGTTGGG	T	TGTGGGTCT	G	GGAGCGTG	C	GCCTCCACAC	360
AGGCCTGTT	G	GGCTTGCTG	A	GGCTTGGGG	G	TTCTGAGA	A	CTCGTCGAG	G	CGAGTGTGCG	420
GCTCCTTCT	A	CCGGCTTAA	A	GGGCCTCAG	T	TTTCGGTGG	G	ATGGCAGCG	G	TATTTGGTTG	480
CAGCCGCG	C	ACGGAAATG	T	AGGGAGTGG	G	CCGCATGGC	C	CCAGGGGAG	G	CTGGGAGACG	540
CCCGGCCG	C	TGGCGGGGA	G	GGTTGCTGC	A	TCGGTTTGC	C	CTGGCGCGC	G	GGGAAGTGGA	600
GCCAGCGTT	T	CTTTACCCC	A	AGTTCCCTG	C	TTAGTCCAG	T	CCCACCGTG	G	TTCTTCAGAG	660
CTGTTCTTG	T	CGTGCTTCA	A	GTATGGGGT	G	ACATTCCGA	A	GTAGTTAAAA		GCCCGTTGAC	720
TCCCGGGGG		CCTGGCACC		TGGCGAGGA	G	GGGGAACAG	A	CAGTGCTCAG	T	TCGGGGTAA	780
GACCACGTG	T	TGAGCAACG	C	CCCACGCCG	T	CTGGGTCG	A	GGGTCCTTCA	T	TCTAGGGCGT	840
GCTGTGCTG	C	GGTTGGCAC	G	GCAACCTGA	A	CTGCAGCA	C	AGTTCTGG	A	CTCGCGCGTG	900
CTTAGACAG	G	AGGTGATGG	G	CACTATTAC	C	TCTTGGCAG	T	GGCCATACG	T	TTTTCCTGGT	960
TAAGTGTTC	T	GTTAAGGG	A	GAGGGAAAT	A	TTTTGATTA	A	TTGAATTTT		AAACCAGATT	1020
TTTCTTTTT		TCAGCAACCA		TGTCCAAGG	G	ACCTGCAGT	T	GGTATTGAT	C	TTGGCACCAC	1080
CTACTCTTG	T	GTGGGTGTT	T	TCCAGCACG	G	AAAAGTCG	A	ATAATTGCC	A	ATGATCAGGG	1140
AAACCGAAC	C	ACTCCAAG	C	ATGTCGCCT	T	TACGGACAC	T	GAACGGTTG	A	TCGGTGATGC	1200
CGCAAAGA	A	CAAGTTGCA	A	TGAACCCAC	A	CAACACAG	T	TTTGGTGAG	T	TCCTAATTTT	1260
AAATGACAG	A	ACAAATATA	A	ACAGGGCTA	G	GAAGCACAA	A	AGTTTATGA	A	ACGTGAGGAG	1320
GGAACTTTT		GATTTTAGA	A	AACTGAGCT	A	GAGAGACTT	G	TTATCAAGT	C	TGTTATAAAA	1380
CAGGTTGTAG		AAACCTTTCA		GGCTGAAAT	C	TGGATAACG	T	AGGAGGTTG	A	AGTTTGAACC	1440
TTTGCTAGGT		ATATGGTAG	T	TGAATTCAC	C	TACCTATGA	A	CTGTTAGGT	A	TTTGAGTAAT	1500
CATGGACTTG		AGTTTTATCT		GAAGAGCTA	T	GAAATTGAA	A	GTGTTTTCA	T	TTGACACCTT	1560
TTACAGATGC		CAACGCTCT	G	ATTGGACGC	A	GATTTGATG	A	TGCTGTTGT	C	CAGTCTGATA	1620
TGAAACATTG		GCCCTTTAT	G	GTGGTGAAT	G	ATGCTGGC	A	GCCCAAGGT	C	CAAGTAGAAT	1680
ACAAGGGAGA		GACCAAAAG	C	TTCTATCC	A	AGGAGGTG	C	TTCTATGGT	T	CTGACAAAGA	1740
TGAAGGAAAT		TGCAGAAGC		TACCTTGG	A	AGGTGAGGT		GGTTTTTC	A	TATGGGGTGC	1800
ATTCCGGAGT		AGTTAAAAG	C	CCGATGACT	C	CCGGGGGCA	C	TGGCACCTG	G	CGAGGGAGGG	1860
GAACAGATGG		GGCTCAGCT	C	AGGGTTAAG	A	CCACGTGCC	C	AACAGTGCC	C	TAGGCTCTCT	1920
AGGTAGATGG		GTCTGTCA	A	ACCAGAAAC	C	AGTGAATCT	T	GACAATTAC	A	CAGTAATTTA	1980
CATTTTGGTG		GGGGGGGTG	C	TCCAGCTGT	T	GTTTCACC	A	CATTAATCC	A	TTTGCTGGAG	2040
TTTGCATATA		TGTAAGTAT	A	ATAGTTACCA	A	ATCTGTGGT	C	TTTTCTTAT	T	TCCTAGACTG	2100
TTACCAATGC		TGTGGTCAC	A	GTGCCAGCT	T	ACTTTAATG	A	CTCTCAGCG	T	CAGGCTACCA	2160
AAGATGCTGG		AACTATTGC	T	GGTCTCAAT	G	TACTTAGA	A	TATTAATG	A	CCAACCTGCTG	2220
CTGCTATTGC		TTACGGCTT	A	GACAAAAAG	G	TATGTACCA	T	TTGTGATGC	A	AGTTCGGATT	2280
ATTTTAAGAT		TAATTTGAT	C	CATCGTAA	T	TTAAATGAG	A	TTGTTTTTA	A	CGGCAGGTTG	2340
GAGCAGAAAG		AAACGTGCT	C	ATCTTTGAC	C	TGGGAGGTG	G	CACTTTTG	A	GTGTCAATCC	2400
TCACTATTGA		GGATGGAAT	C	TTTGAGGT	C	AGTCTACAG	C	TGGAGACAC	C	CACTTGGGTG	2460
GAGAAGATTT		TGACAACCG	A	ATGGTCAAC	C	ATTTTATTG	C	TGAGTTTAA	G	CGCAAGCATA	2520
AGAAGGACAT		CAGTGAGAA	C	AAGAGAGCT	G	TAAGACGC	C	CCGTACTGC	T	TGTGACGTCG	2580

CTAAGCGTAC	CCTCTCTTCC	AGCACCCAGG	CCAGTATTGA	GATCGATTCT	CTCTATGAAG	2640
GAATCGACTT	CTATACCTCC	ATTACCCGTG	CCCgATTtGA	AGAActGAAT	GCTGACCTGT	2700
TCCGTGGCAC	CCTGGACCCA	GTAAGAAAAG	CCCTTCGAGA	TGCCAAACTA	GACAAGTCAC	2760
AGATTCATGA	TATTGTCCTG	GTTGGTGGTT	CTACTCGTAT	CCCCAAGATT	CAGAAGCTTC	2820
TCCAAGACTT	CTTCAATGGA	AAAGAACTGA	ATAAGAGCAT	CAACCCTGAT	GAAGCTGTTG	2880
CTTATGGTGC	AGGTAACAAT	GGTATCTCAA	TTAACCCTAA	AGGCAGGCAG	GCCCAAGGTG	2940
ACTCGCTGTG	ATGAGTGATT	GTTAAACATT	CGTAGTTTCC	ACCAAAAGCT	TGGCTAATGA	3000
TGGCAACACC	TTCCTTGGAT	GTCTGAGCGA	GTGATAGTTA	AAACAGGAGC	TATGTACTGG	3060
GTTTTCTTTT	AACTTCTTTT	AACGTTAACT	TTTTGTTTGC	TAGCTGTCCA	GGCAGCCATC	3120
TTGTCTGGAG	ACAAGTCTGA	GAATGTTCAA	GATTTGCTGC	TCTTGGATGT	CACTCCTCTT	3180
TCCCTTGGTA	TTGAAACTGC	TGGTGGAGTC	ATGACTGTCC	TCATCAAGCG	TAATACCACC	3240
ATTCTTACCA	AGCAGACACA	GACCTTCACT	ACCTATTCTG	ACAACCAGCC	TGGTGTGCTT	3300
ATTCAGGTAT	GTTTCTGTAC	TTCTCTTGTT	TGGCTTACTG	ATAACAGATA	AAGGGAAGTC	3360
TTGACTGACT	CGCTATGATG	ATGGATTCCA	AAACCATTCC	TAGTTTCCAC	CAGAAAGTCT	3420
TATGTTGGCC	AGTTCCTTCC	TTGGATGTTT	GAGCGACCAT	TCTTCCTTAG	CAGGACCCTA	3480
GCACTGTCAC	AGACCTGGAG	TCCATTGTAG	TAATTTGTTT	TATTTCTTAC	CAAGGTTTAT	3540
GAAGGCGAGC	GTGCCATGAC	AAAGGATAAC	AACCTGCTTG	GCAAGTTTGA	ACTCACAGGC	3600
ATACCTCCTG	CACCCCGAGG	TGTTCCCTCAG	ATTGAAGTCA	CTTTTGACAT	TGATGCCAAT	3660
GGTATACTCA	ATGTCTCTGC	TGTGGACAAG	AGTACGGGAA	AAGAGAACAA	GATTACTATC	3720
ACTAATGACA	AGGGTAAGGA	GGCACTGTCA	TCTGGTCTTG	ACAGGGATAA	TGGTATTTCA	3780
ATTGAGTTAC	TGGTGAATAA	GGGCGTCTAG	CTAAGAGAAA	CTAGAGTTAC	ACATACACAG	3840
GTAATTTAAG	GCTTTTACTT	AGAGTTAATT	TCTTTCCTAG	GCCGTTTGAG	CAAGGAAGAC	3900
ATTGAACGTA	TGGTCCAGGA	AGCTGAGAAG	TACAAAGCTG	AAGATGAGAA	GCAGAGGGAC	3960
AAGGTGTCAT	CCAAGAATTC	ACTTGAGTCC	TATGCCTTCA	ACATGAAAGC	AACTGTTGAA	4020
GATGAGAAAC	TTCAAGGCAA	GATTAACGAT	GAGGACAAAC	AGAAGATTCT	GGACAAGTGT	4080
AATGAAATTA	TCAACTGGCT	TGATAAGAAT	CAGGTTTGTG	TTTTTTTTTT	TTTTTTTCCT	4140
CCCCACGCA	ATGGAGGGGA	AGGGGATGGT	AAACCAAGCT	TGAGCTGGAT	TTCAAGTGTAG	4200
GGTCACAATG	ATGAATGGTC	CAAAACATTC	GCGGTTTCCA	CCAGAATTCA	AGGTGTTGGC	4260
AACTACCTTC	CTTGGATGTC	TGAGTGACCC	AAGATGTTAA	GGAGAATAAA	GGCCCTATTT	4320
TAATGTTGGT	ATGGGCCCTC	TTGTAAGAGT	TGCTCCAGAA	CTTTTAGTAT	CAGATTGCGT	4380
CAGGGAGAAA	GAAGGGTTAT	TAACATTAAA	AGAACTTGCA	GTAATTCCTT	TTTCTCTTCC	4440
TCAGACTGCT	GAGAAGGAAG	AATTTGAACA	TCAACAGAAA	GAGCTGGAGA	AAGTTTGCAA	4500
CCCCATCATC	ACCAAGCTGT	ACCAGAGTGC	AGGAGGCATG	CCAGGAGGAA	TGCTGGGGG	4560
ATTTCTTGGT	GGTGGAGCTC	CTCCCTCTGG	TGGTGCTTCC	TCAGGGCCCA	CCATTGAAGA	4620
GGTTGATTAA	GCCAACCAAG	TGTAGATGTA	GCATTGTTCC	ACACATTTAA	AACATTTGAA	4680
GGACCTAAAT	TCGTAGCAAA	TTCTGTGGCA	GTTTTAAAAA	GTTAAGCTGC	TATAGTAAGT	4740
TACTGGGCAT	TCTCAATACT	TGAATATGGA	ACATATGCAC	AGGGGAAGGA	AATAACATTG	4800
CACTTTATAC	ACTGTATTGT	AAGTGGAAAA	TGCAATGTCT	TAAATAAAAC	TATTTAAAAA	4860
TGGCACCATA	CAATTGCTTT	GAGTCTTTAA	ATAATCTCCC	AGGCCAGCGG	TGGGAGAAGT	4920
AGGCTTAGGT	GATTATGTGA	CTCTTACTTT	CTCCTTCCTC	TTAAGCTTGA	GTTAACAAGG	4980
GCTGGGTGGC	AAGTTGCCCT	TCAGAGCATG	TGGATGGTAC	ATTTTGGAAT	TCAGAGCTTT	5040
GAGAAGGGGA	GCATAAGAAA	TTGGATCTGG	ATCAAATAAA	CCTTAGTCCT	TAGGCTGGAG	5100
AGGCAGAAGC	TGACTTAATG	GTGTTTCTA	AACTTATTCT	GTGTGTAAGC	CTGCCTAGGA	5160
GCAGAGGCTT	TCCTGGAGGG	TTGTGCTAGA	TGAGTAAGAA	TTTAGATACA	GAATCAAATA	5220
ATGGGCAAGT	AATATTAAGC	TACATGGCAG	AGGTATCTGA	ATGTCAATCC	CTTATATGAG	5280
CCACTGCCCT	GTGGGCTTCC	ATTTCTTCTG	AGTTAAGATT	ATTCAGAAGG	TCGGGGATTG	5340
GAGCTAAGCT	GCCACCTGGT	TAATTAAGGT	CCCAACAGTG	AGTTGTGATA	GCCTAGGGGA	5400
GCAGGCTG						5408

Figure 6


FEATURES	Location/Qualifiers
gene	31..1971
	/gene="hsc73"
CDS	31..1971
	/gene="hsc73"
	/codon_start=1
	/product="heat shock 73 protein"
	/db_xref="PID:g861213"
	/translation="MSKGPVAVGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAF
	TDTERLIGDAAKNQVAMNPTNTVFDKRLIGRRFDDAVVQSDMKHWPFMVNDAGRPK
	VQVEYKGETKSFYPPEVSSMVLTKMKEIAEAYLGKTVTNNAVVTVPAYFNDSQRQATKD
	AGTIAGLNVLRINEPTAAAIAYGLDKKVGAEARNVLI FDLGGGTFDVSILTIEDGIFE
	VKSTAGDTHLGGEDFDNRMVNHFIAEFKRKHKKDI SENKRAVRRRLRTACERAKRTLSS
	STQASIEIDSLYEGIDFYTSITRARFEELNADLFRGTLDPVEKALRDAKLDKSQIHDI
	VLVGGSTRIPKIQKLLQDFNKGELNKSINPDEAVAYGAAVQAAILSGDKSENVQDLL
	LLDVTPLSLGIETAGGVMTVLIKRNTTIPTKQTQTFTTYSNQPGLVLIQVYEGERAMT
	KDNNLLGKFELTGIPAPRGVPQIEVTFDIDANGILNLSAVDKSTGKENKITITNDKG
	RLSKEDIERMVQEAKEYKADEKQDRKVSSKNSLESYAFNMKATVEDEKLQGKINDED
	KQKILDKCNEIISWLDKNQTAEKEEFEHQKKELEKVCNPIITKLYQSAGGMPGMPGG
	FPGGGAPPSGASSGPTIEEVD"

1	cagcacagct	gggcctacac	acaagcaacc	atgtctaagg	gacctgcagt	tggcattgat
61	ctcggcacca	cctactcctg	tgtgggtgtc	ttccagcatg	gaaaggtgga	aattattgcc
121	aatgaccagg	gtaaccgcac	cacaccaagc	tatgttgctt	tcacggacac	agagagatta
181	attggggatg	cggccaagaa	tcaggttgca	atgaacccca	ccaacacagt	ttttgatgcc
241	aaacgtctga	tcgggcgtag	gtttgatgat	gctgttggtc	agtctgatat	gaagcactgg
301	cccttcattg	tggtgaatga	tcgaggcagg	cccaagggtc	aagtgggaata	caaaggggag
361	acaaaaaagt	tctacccaga	ggaagtgtcc	tccatgggtc	tgacaaagat	gaaggaaatt
421	gcagaagcgt	acctcggaaa	gactgttacc	aacgctgtgg	tcacagtgcc	cgcttacttc
481	aatgactctc	agcgacaggc	aacaaaagat	gctggaacta	ttgctggcct	caatgtactt
541	cgaatcatca	atgaaccaac	tgctgctgct	attgcttatg	gcttagataa	gaaggtcgga
601	gctgaaagaa	atgtgctcat	ttttgacttg	ggagggtggc	cttttgatgt	gtcaatcctc
661	actattgagg	atggaatttt	tgaggtcaaa	tcaacagctg	gagacaccca	cttaggtgga
721	gaagattttg	acaaccgaat	ggtcaatcat	ttcattgctg	agttcaagcg	aaagcacaaag
781	aaagacatca	gtgagaacaa	gagagctgtc	cgccgtctcc	gcacggcctg	cgagcgggcc
841	aagcgcaccc	tctcctccag	caccacaggc	agtattgaga	ttgattctct	ctatgagggg
901	attgacttct	atacctccat	tacccgggct	cgatttgagg	agttgaatgc	tgacctgttc
961	cgtggcacac	tggaccctgt	agagaaggcc	cttcgagatg	ccaagctgga	caagtacacg
1021	atccatgata	ttgtcttggt	gggtggttct	accagaatcc	ccaagattca	gaaacttctg
1081	caagacttct	tcaatggaaa	agagctgaac	aagagcatta	accccgatga	agctgttgcc
1141	tatggtgcag	ctgtccaggc	agccattcta	tctggagaca	agtctgagaa	cgttcaggat
1201	ttgctgctct	tggtatgtcac	tcctctttcc	cttggtattg	aaactgctgg	cggagtcattg
1261	actgtcctca	tcaagcgcaa	taccaccatc	cccaccaagc	agacacagac	tttcaccacc
1321	tactctgaca	accagcctgg	tgtactcatt	cagggtgatg	aagggtgaaag	ggccatgacc
1381	aaggacaaca	acctgcttgg	aaagttcgag	ctcacaggca	tcctccagc	accccggtggg
1441	gtccctcaga	ttgaggttac	ttttgacatc	gatgccaatg	gcatectcaa	tgtttctgct
1501	gtagataaga	gcacaggaaa	ggagaacaa	atcaccatca	ccaatgacaa	gggcccgttg
1561	agtaaggaa	atattgagcg	catggtccaa	gaagctgaga	agtacaaggc	tgaggatgag
1621	aagcagagag	ataaggtttc	ctccaagaac	tactggaggt	cctatgcctt	caacatgaaa
1681	gcaactgtgg	aagatgagaa	acttcaaggc	aagatcaatg	atgaggacaa	acagaagatt
1741	cttgacaagt	gcaatgaaat	catcagctgg	ctggataaga	accagactgc	agagaaggaa
1801	gaatttgagc	atcagcagaa	agaactggag	aaagtctgca	accctatcat	taccaagctg
1861	taccagagt	caggtggcat	gcctggggga	atgcctggtg	gcttcccagg	tggaggagct
1921	cccccatctg	gtggtgcttc	ttcaggcccc	accattgaag	aggtggatta	agtcagttca
1981	agaagaaggt	gtagctttgt	tccacaggga	cccaaaacaa	gtaacatgga	ataataaaaac
2041	tattcaaat	gg				

9/9

Fig.7.



# INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/GB 98/03375

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12Q1/68 C07K14/47 C07K16/18 C12N15/12 C12N15/00  
C12N5/10 A61K38/16 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	UDONO H ET AL: "COMPARISON OF TUMOR-SPECIFIC IMMUNOGENICITIES OF STRESS-INDUCED PROTEINS GP96, HSP90, AND HSP70" JOURNAL OF IMMUNOLOGY, vol. 152, 1994, pages 5398-5403, XP002912526 see page 5398, paragraph 2 - page 5399, paragraph 1	1,2,18
A	MULTHOFF G ET AL: "A stress-inducible 72-kDa heat-shock protein (hsp72) is expressed on the surface of human tumor cells, but not on normal cells" INTERNATIONAL JOURNAL OF CANCER, vol. 61, 10 April 1995, pages 272-279, XP002090859 see the whole document	1-20



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

31 March 1999

Date of mailing of the international search report

13/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Osborne, H

# INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/GB 98/03375

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	YANO M ET AL: "Expression and roles of heat shock proteins in human breast cancer" JAPANESE JOURNAL OF CANCER RESEARCH, vol. 89, no. 9, September 1996, pages 908-15, XP002098505 see the whole document ---	1-20
X	WO 97 06685 A (SLOAN KETTERING INST CANCER ;HOE MEE H (US); HOUGHTON ALAN (US); M) 27 February 1997 see the whole document ---	25,26
A	see the whole document ---	1,20-24
X	WO 94 11513 A (LUKACS KATALIN VERONIKA ;MEDICAL RES COUNCIL (GB); LOWRIE DOUGLAS) 26 May 1994 see the whole document ---	25,26
A	see the whole document ---	21-24
X	WO 96 10411 A (SINAI SCHOOL MEDICINE) 11 April 1996 see the whole document -----	25,26
A	see the whole document -----	21-24



# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. Application No

PCT/GB 98/03375

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9706685 A	27-02-1997	AU 6849396 A AU 6898496 A AU 6952896 A CA 2229543 A CA 2229595 A EP 0851764 A EP 0888053 A WO 9706828 A WO 9706821 A	12-03-1997 12-03-1997 12-03-1997 27-02-1997 27-02-1997 08-07-1998 07-01-1999 27-02-1997 27-02-1997
WO 9411513 A	26-05-1994	AU 690085 B AU 5430794 A CA 2149309 A EP 0670899 A JP 8503132 T	23-04-1998 08-06-1994 26-05-1994 13-09-1995 09-04-1996
WO 9610411 A	11-04-1996	US 5750119 A AU 2281995 A CA 2201498 A CN 1167440 A EP 0784477 A JP 10506628 T	12-05-1998 26-04-1996 11-04-1996 10-12-1997 23-07-1997 30-06-1998